Michael Dube Sells 1,871 Shares of Intellia Therapeutics (NASDAQ:NTLA) Stock

Intellia Therapeutics, Inc. (NASDAQ:NTLA) CAO Michael Dube sold 1,871 shares of the company’s stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $17.38, for a total value of $32,517.98. Following the completion of the sale, the chief accounting officer owned 55,266 shares of the company’s stock, valued at $960,523.08. This trade represents a 3.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Intellia Therapeutics Stock Performance

NASDAQ NTLA opened at $19.96 on Friday. The stock’s fifty day moving average is $12.88 and its two-hundred day moving average is $10.32. The firm has a market capitalization of $2.14 billion, a P/E ratio of -4.26 and a beta of 2.37. Intellia Therapeutics, Inc. has a fifty-two week low of $5.90 and a fifty-two week high of $21.47.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Thursday, August 7th. The company reported ($0.99) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.04. The business had revenue of $14.25 million during the quarter, compared to the consensus estimate of $12.26 million. Intellia Therapeutics had a negative return on equity of 57.48% and a negative net margin of 908.48%.The company’s revenue for the quarter was up 104.3% on a year-over-year basis. During the same period last year, the company earned ($1.52) EPS. As a group, sell-side analysts forecast that Intellia Therapeutics, Inc. will post -5.07 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on NTLA shares. JMP Securities reiterated a “market perform” rating on shares of Intellia Therapeutics in a report on Friday, September 19th. Guggenheim reiterated a “buy” rating and issued a $14.00 price objective on shares of Intellia Therapeutics in a report on Wednesday, August 13th. Wells Fargo & Company reissued an “overweight” rating and set a $45.00 target price (down previously from $50.00) on shares of Intellia Therapeutics in a research note on Friday, August 8th. Wall Street Zen upgraded Intellia Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 6th. Finally, HC Wainwright increased their price target on Intellia Therapeutics from $25.00 to $30.00 and gave the stock a “buy” rating in a report on Friday, September 19th. Eleven analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $27.39.

Hedge Funds Weigh In On Intellia Therapeutics

Hedge funds have recently made changes to their positions in the company. ARK Investment Management LLC boosted its position in shares of Intellia Therapeutics by 3.8% in the 1st quarter. ARK Investment Management LLC now owns 13,011,015 shares of the company’s stock valued at $92,508,000 after purchasing an additional 474,629 shares during the period. Vanguard Group Inc. lifted its stake in Intellia Therapeutics by 5.5% in the first quarter. Vanguard Group Inc. now owns 10,752,031 shares of the company’s stock valued at $76,447,000 after buying an additional 561,978 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Intellia Therapeutics by 5.1% in the second quarter. Geode Capital Management LLC now owns 2,606,222 shares of the company’s stock valued at $24,449,000 after acquiring an additional 126,049 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Intellia Therapeutics by 73.0% in the second quarter. JPMorgan Chase & Co. now owns 940,483 shares of the company’s stock valued at $8,822,000 after acquiring an additional 396,858 shares during the period. Finally, Armistice Capital LLC grew its position in shares of Intellia Therapeutics by 78.6% during the second quarter. Armistice Capital LLC now owns 650,000 shares of the company’s stock worth $6,097,000 after acquiring an additional 286,000 shares during the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.